Abstract
Introduction: Non-Small Cell Lung Cancer (NSCLC) is an aggressive malignancy with poor overall survival that accounts for up to 85% of lung cancer diagnoses. The use of immunotherapy in the form of checkpoint inhibition, to enhance the immune system’s ability to attack malignant cells, has been a promising addition to treatment options in advanced NSCLC.
Results: Such therapeutic agents aimed at the Programmed Death 1 (PD-1) receptor or Programmed Death Ligand 1 (PD-L1) have revealed promising results against many types of cancer including NSCLC. Examples of these agents include nivolumab, pembrolizumab, BMS-936559, atezolizumab, and MEDI4736, of which the first two are approved by US FDA in the second line treatment of advanced NSCLC.
Discussion: Impressive improvements in objective responses from PD-1 blockade were found in both first line therapy as well as treatment after progression on platinum based therapy. In addition, the safety profile is favorable with significantly lower grade 3-4 adverse events compared to standard of care. The optimal selection criteria and factors that show an increased response to therapy are still being determined.
Keywords: Immune Checkpoint Inhibitors, Non-Small-Cell Lung Cancer.
Reviews on Recent Clinical Trials
Title:Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer
Volume: 11 Issue: 4
Author(s): Anshu Giri, Simrit S. Walia and Ajeet Gajra
Affiliation:
Keywords: Immune Checkpoint Inhibitors, Non-Small-Cell Lung Cancer.
Abstract: Introduction: Non-Small Cell Lung Cancer (NSCLC) is an aggressive malignancy with poor overall survival that accounts for up to 85% of lung cancer diagnoses. The use of immunotherapy in the form of checkpoint inhibition, to enhance the immune system’s ability to attack malignant cells, has been a promising addition to treatment options in advanced NSCLC.
Results: Such therapeutic agents aimed at the Programmed Death 1 (PD-1) receptor or Programmed Death Ligand 1 (PD-L1) have revealed promising results against many types of cancer including NSCLC. Examples of these agents include nivolumab, pembrolizumab, BMS-936559, atezolizumab, and MEDI4736, of which the first two are approved by US FDA in the second line treatment of advanced NSCLC.
Discussion: Impressive improvements in objective responses from PD-1 blockade were found in both first line therapy as well as treatment after progression on platinum based therapy. In addition, the safety profile is favorable with significantly lower grade 3-4 adverse events compared to standard of care. The optimal selection criteria and factors that show an increased response to therapy are still being determined.
Export Options
About this article
Cite this article as:
Giri Anshu, Walia S. Simrit and Gajra Ajeet, Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer, Reviews on Recent Clinical Trials 2016; 11 (4) . https://dx.doi.org/10.2174/1574887111666160724181330
DOI https://dx.doi.org/10.2174/1574887111666160724181330 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microarray: An Approach for Current Drug Targets
Current Drug Metabolism Nimesulide is a Selective COX-2 Inhibitory, Atypical Non-Steroidal Anti-Inflammatory Drug
Current Medicinal Chemistry miR-629-3p Level Significantly Predicts Prognosis in Glioblastoma Patients Treated with Temozolomide Chemotherapy
Current Signal Transduction Therapy Potential Applications of FDG-PET/CT in COPD: A Review of the Literature
Current Molecular Imaging (Discontinued) Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer
Current Pharmaceutical Biotechnology Neuronal Generation from Somatic Stem Cells: Current Knowledge and Perspectives on the Treatment of Acquired and Degenerative Central Nervous System Disorders
Current Gene Therapy Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Promising Gene Therapy Using an Adenovirus Vector Carrying REIC/Dkk-3 Gene for the Treatment of Biliary Cancer
Current Gene Therapy Effects of Drug Transporters on Pharmacological Responses and Safety
Current Drug Metabolism Identifying Candidates for Breast Cancer using Interactions of Chemicals and Proteins
Combinatorial Chemistry & High Throughput Screening Targeting Inhibitor of Apoptosis Proteins (IAPs) for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Vascular Endothelial Growth Factor (VEGF) Biochemistry and Development of Inhibitory Drugs
Current Drug Therapy Strategies to Overcome Drug Resistance of Receptor Tyrosine Kinaseaddicted Cancer Cells
Current Medicinal Chemistry An Overview of Promising Biomarkers in Cancer Screening and Detection
Current Cancer Drug Targets Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer
Current Computer-Aided Drug Design Editorial: (Thematic Issue Cancer Immunotherapy: Does an Increasing Arsenal of Tools Point to More Fruitful Avenues for Research?)
Anti-Cancer Agents in Medicinal Chemistry Synthetic and Biological Aspects of Thiadiazoles and their Condensed Derivatives: An Overview
Current Topics in Medicinal Chemistry